Immunotherapy for neuroblastoma by hematopoietic cell transplantation and post-transplant immunomodulation

Shifra Ash*, Nadir Askenasy

*Corresponding author for this work

Research output: Contribution to journalReview articlepeer-review


Neuroblastoma represents a relatively common childhood tumor that imposes therapeutic difficulties. High risk neuroblastoma patients have poor prognosis, display limited response to radiochemotherapy and may be treated by hematopoietic cell transplantation. Allogeneic and haploidentical transplants have the distinct advantage of reinstitution of immune surveillance, reinforced by antigenic barriers. The key factors favorable to ignition of potent anti-tumor reactions are transition to adaptive immunity, recovery from lymphopenia and removal of inhibitory signals that inactivate immune cells at the local and systemic levels. Post-transplant immunomodulation may further foster anti-tumor reactivity, with positive but transient impact of infusions of lymphocytes and natural killer cells both from the donor, the recipient or third party. The most promising approaches include introduction of antigen-presenting cells in early post-transplant stages and neutralization of inhibitory signals. Further studies will likely shed light on the nature and actions of suppressor factors within tumor stroma and at the systemic level.

Original languageEnglish
Article number103956
JournalCritical Reviews in Oncology/Hematology
StatePublished - May 2023
Externally publishedYes


  • Antigen-presenting cells
  • Graft versus host disease
  • Graft versus tumor
  • Hematopoietic cell transplantation
  • Lymphocyte infusion
  • Neuroblastoma


Dive into the research topics of 'Immunotherapy for neuroblastoma by hematopoietic cell transplantation and post-transplant immunomodulation'. Together they form a unique fingerprint.

Cite this